New combo therapy aims to boost rectal cancer remission

NCT ID NCT07198165

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with locally advanced rectal cancer that hasn't spread. It tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation plus chemotherapy and targeted therapy) can lead to a complete disappearance of the cancer. About 104 participants will receive either the standard combination or the standard plus immunotherapy to see which works better and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIOTHERAPY IMMUNOTHERAPY RECTAL ADENOCARCINOMA RECTAL CANCER RECTAL CANCER PATIENTS RECTAL CANCER, RADIOTHERAPY TARGETED THERAPY TOTAL NEOADJUVANT THERAPY TOTAL NEOADJUVANT TREATMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••